James P. Brady
Human Resources Officer bij SPERO THERAPEUTICS, INC.
Profiel
James P.
Brady is currently the Chief Human Resource Officer at Spero Therapeutics, Inc. Previously, he held the position of Vice President-Human Resources at Intarcia Therapeutics, Inc. and was the Chief Human Resources Officer at uniQure NV.
He received a graduate degree from Harvard University and an undergraduate degree from Marietta College.
Actieve functies van James P. Brady
| Bedrijven | Functie | Begin |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Human Resources Officer | - |
Eerdere bekende functies van James P. Brady
| Bedrijven | Functie | Einde |
|---|---|---|
| UNIQURE N.V. | Human Resources Officer | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Human Resources Officer | - |
Opleiding van James P. Brady
| Harvard University | Graduate Degree |
| Marietta College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| UNIQURE N.V. | Health Technology |
| SPERO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
